14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Fri, 26 Apr 2024

Trading levels for IDXG

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.43 0.82 %
R2 1.43 0.552 %
R1 1.43 0.386 %
Current price: 1.42
Support S1 1.42 -0.151 %
S2 1.42 -0.317 %
S3 1.41 -0.586 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 1.66 16.70 %
R2 1.63 14.59 %
R1 1.45 1.93 %
Current price 1.42
Support S1 1.35 -5.10%
S2 1.20 -15.64%
S3 1.09 -23.66%

IDXG Predictions History

4 years ago
NameNotImportant predicted that IDXG for 2019-05-06 is going $0.82 (6.23%)

5 years ago
JS predicted that IDXG for 2018-10-01 is going $1.53 (-8.93%)

6 years ago
JS predicted that IDXG for 2017-11-30 is going $1.15 (0.00%)

6 years ago
JS predicted that IDXG for 2017-09-19 is going $1.52 (-3.80%)

6 years ago
JS predicted that IDXG for 2017-09-05 is going $1.40 (-17.65%)

6 years ago
Victor.Li.10341 predicted that IDXG for 2017-09-05 is going $1.42 (-16.47%)

Rank:

6 years ago
JuanC Villegas predicted that IDXG for 2017-08-23 is going $1.35 (0.00%)

6 years ago
JS predicted that IDXG for 2017-08-18 is going $1.21 (-1.63%)

6 years ago
Victor..Li.8930 predicted that IDXG for 2017-08-18 is going $1.39 (13.01%)

6 years ago
Victor..Li.8930 predicted that IDXG for 2017-08-17 is going $1.58 (22.48%)

Click to get the best stock tips daily for free!

About Interpace Diagnostics Group

Interpace Diagnostics Group Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited n... IDXG Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT